STUDIES AND FDA PAGES / 07
BPC-157 TB-500 References: Where each claim came from
A number beside a claim helps you find its source below. Each link opens either the study paper or the FDA rule page.
Which sources cover each substance?
The BPC-157 TB-500 references let you check each claim. Papers on BPC-157 cover cut rat tendons and blood flow. One paper identifies TB-500 as the short piece cut from Thymosin Beta-4. Other papers tested the whole protein rather than the short piece for cell movement and wounds. Sports papers tested for the short piece. Keeping those sources apart stops a whole-protein result from becoming proof about the mix.
One 2025 review found almost no work on BPC-157 in people. A 2026 review found little sound proof of human safety and said serious harm was possible. Another 2025 review also found little human work. None proved that the pair helps or is safe. FDA pages explain the Category 2 safety group used for pharmacy mixing.
Marks from [1] through [18] point to the sources below. You can open each study or FDA page. The links show whether a test used human beings, animals, or lab dishes. That helps you judge how closely each finding fits your health.
- Staresinic M, et al. Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. J Orthop Res. 2003;21(6):976-983. (BPC-157 chemical identity and PK reference points cited throughout.) ↗
- Hsieh MJ, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med (Berl). 2017;95:323-333. ↗
- Irobi E, et al. Structural basis of actin sequestration by thymosin-beta4: implications for WH2 proteins. EMBO J. 2004. ↗
- Goldstein AL, Hannappel E, Sosne G, Kleinman HK. Thymosin beta4: a multi-functional regenerative peptide. Basic properties and clinical applications. Expert Opin Biol Ther. 2012. ↗
- Staresinic M, et al. Effects of pentadecapeptide BPC 157 on the rabbit/rat transected Achilles tendon model (transected-tendon healing and tendocyte outgrowth). J Orthop Res. 2003;21(6):976-983. ↗
- Philp D, et al. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mech Ageing Dev. 2004. ↗
- Esposito S, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Test Anal. 2012. ↗
- Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. ↗
- Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS J. 2025. (36 studies, 35 preclinical, 1 human; "no clinical safety data"; no mention of TB-500 or any combination/blend.) ↗
- Mendias CL, Awan TM. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. Sports Med. 2026. (Lists both BPC-157 and TB-500/thymosin beta-4; rigorous human safety data scarce; potential for serious harm; largely outside regulatory oversight.) ↗
- Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025. (Human data limited to three pilot studies; should be considered investigational.) ↗
- Human single-agent pharmacokinetic and safety reference points for full-length Thymosin Beta-4 (NOT the TB-500 heptapeptide): intravenous Tbeta4 well tolerated to 1260 mg with dose-proportional PK (Ruff et al., Phase 1, 40 volunteers) and to 25 microg/kg single / 5 microg/kg-daily x 10 days (first-in-human study, 2021), as summarized in the dosage-research context of the compound corpus. See also ref [4] for the consolidated Thymosin Beta-4 clinical-development review. ↗
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. (BPC-157 (free base) / BPC-157 acetate placed in Category 2 for 503A compounding; list entry effective September 29, 2023; page verified loading and containing the BPC-157 entry on 2026-05-29.) ↗
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. ("Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" placed in Category 2 for 503A compounding; list entry effective September 29, 2023; page verified loading and containing the entry on 2026-05-29.) ↗
- U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. (Definitions of Category 1 and Category 2; the 503A/503B framework; bulk-substance eligibility rules; PCAC role; FDA approval of a finished drug is separate from compounding eligibility. Verified 2026-05-29.) ↗
- U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. (Public calendar listing BPC-157 and TB-500 among substances "being considered for inclusion on the 503A Bulks List"; a scheduled discussion under evaluation, NOT a decision or outcome. Verified 2026-05-29.) ↗
- Cha HJ, Jeong MJ, Kleinman HK. Role of thymosin beta4 in tumor metastasis and angiogenesis. J Natl Cancer Inst. 2003. ↗
- Ho ENM, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta4, in equine urine and plasma by liquid chromatography-mass spectrometry. J Chromatogr A. 2012. ↗
- Ruff D, et al. A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Ann N Y Acad Sci. 2010. ↗
- et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin beta4 in healthy Chinese volunteers. J Cell Mol Med. 2021. ↗